Margit Mahlapuu appointed as CSO of Pergamum AB
SWEDEN, STOCKHOLM – 2 May, 2012. Pergamum AB today announced that Dr. Margit Mahlapuu was appointed as the company’s Chief Scientific Officer (CSO).
Pergamum AB was formed in 2009 with the objective of synergetically aggregating a number of programs in the field of locally delivered biopharmaceuticals. The company has operations in several locations in Sweden. The company announced today that Dr. Margit Mahlapuu will take on the role as Chief Scientific Officer in Pergamum.
”I would like to congratulate and welcome Dr. Margit Mahlapuu in her new role as Chief Scientific Officer. She provides the strength and continuity that we need in the development organization of our company.” said Jonas Ekblom, CEO of Pergamum. “This is part of an ongoing consolidation process. Coordinating our company's efforts in the most important development programs, while streamlining our operations, will reduce ongoing operating expenses and increase quality.”
The company continues clinical development of the core programs: PXL-01, DPK-060 and LL-37 for the treatment of wounds and skin infections. Moreover, Pergamum will seek to co-develop some of its initiatives in strategic partnerships with other companies. Dr. Margit Mahlapuu, who also holds a position as Associate Professor in Medicine at the University of Gothenburg, has more than 15 years of life science experience and has held several senior positions in small and large pharmaceutical companies. Most recently, Dr. Mahlapuu has served in the role as Executive Director for the PXL-01 technology platform.
For further information, please contact:
Jonas Ekblom, CEO,Pergamum AB
Phone: +46 (0)70 551 66 60, e-mail: firstname.lastname@example.org
TO THE EDITORS
About Pergamum AB
Pergamum is a biopharmaceutical company specialized in the development of therapeutic peptides for local application in infections and wounds. Within Pergamum, companies and projects are managed as fully integrated operating units. The company’s vision is to develop a portfolio of unique development programs representing high medical value that ultimately, through global partnerships, will result in first-in-class and first-in-category products. The current development pipeline includes three therapeutic peptides that have reached clinical stage, with potential for use in several medical applications. Please visit our web site: www.pergamum.com